Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 31st, the Senator disclosed that they had sold between $1,001 and $15,000 ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more ...

Investment analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Abbott Laboratories in a report ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...